HistoSonics Secures $250M in Growth Financing
HistoSonics announced the closure of an oversubscribed $250 million financing round to support the expansion of its histotripsy platform.
The financing was led by the company's new ownership group, a syndicate of private and public investors who acquired a majority stake in HistoSonics for $2.25 billion in August, along with additional investors Thiel Bio and Founders Fund.
The funds will be used to support the ongoing commercial expansion of the Edison histotripsy system into new markets.
About the Edison Platform
The Edison platform uses focused ultrasound energy, delivered via a robotic arm, to provide histotripsy for the noninvasive destruction of tumors.
Edison mechanically destroys and liquifies targeted tissue and tumors without the invasiveness or toxicity of traditional procedures.
The platform has received its first FDA de novo authorization in the U.S. and is the first and only histotripsy platform cleared for clinical use globally.
Author's summary: HistoSonics raises $250M for histotripsy platform expansion.